Amendments have been suggested by the British Generic Manufacturers Association to UK government proposals to overhaul the country’s statutory scheme for branded medicine pricing.
BGMA Suggests Tweaks To UK Statutory Pricing Scheme Proposals
Generics And Biosimilars Body Continues To Welcome Recognition Of Competition Impact
UK generics and biosimilars industry association the BGMA has published a formal response to a government consultation on the statutory scheme for branded medicine pricing, welcoming the recognition of the impact of competition in the government’s proposals but suggesting amendments to “minimize unintended consequences and align it to how the market operates.”
More from Policy & Regulation
More from Generics Bulletin
• By
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.